Daratumumab and hyaluronidase-fihj is now FDA-approved for newly diagnosed multiple myeloma patients ineligible for ASCT, in combination with VRd. The phase 3 CEPHEUS trial showed significant ...
A quadruplet regimen for treating transplant-ineligible, newly diagnosed multiple myeloma (MM), combining the oral drug ixazomib with daratumumab, lower-dose lenalidomide, and dexamethasone (Dara-RId) ...
Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care Approval marks the twelfth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results